Fresenius Medical Care Ventures
Fresenius Medical Care Ventures was established to invest in start-ups and early-stage companies in the healthcare sector. The investments are targeted to support Fresenius Medical Care’s corporate strategy to grow continuously in our core business and to expand into new business areas. Fresenius Medical Care Ventures is complementing the corporate activities in external innovation.
Fresenius Medical Care Ventures invests in early stage companies that develop products, technologies and therapies which will have a significant value for the patient and for the healthcare system.
Sectors of Interest
Products and technologies of interest include medical devices, patient monitoring, eHealth solutions, regenerative medicine and pharmaceuticals which provide innovative and potentially transformative approaches in the following therapeutic sectors:
- Chronic Kidney Disease and Dialysis
- Intensive Care Medicine
- Cardiovascular Disease
- Extracorporeal Therapies
Alucent Biomedical is a privately held medical technology company founded to transform the way vascular disease is treated. Alucent develops products using Natural Vascular Scaffolding (AlucentNVS) technology, a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining vascular patency.
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation.
ExThera Medical is developing revolutionary medical devices that address unmet clinical needs in the treatment of bloodstream infections and pathogen-reduction in blood banking.
Magenta Medical is developing two types of novel self-expanding miniaturized pumps for heart-failure patients.
- The percutaneous Left Ventricular Assist Device (pLVAD) is a next-generation low-profile arterial pump, intended for temporary support of patients undergoing high-risk coronary interventions and the treatment of patients admitted with cardiogenic shock.
- The Transcatheter Renal Venous Decongestion (TRVD™) System is a venous pump intended for the treatment of hospitalized patients with acutely decompensated heart failure, by reducing the renal venous pressure and decompressing the kidneys.
Memo Therapeutics AG
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company is developing a proprietary therapeutic antibody lead pipeline with an initial focus on infectious diseases and cancer. The lead program for therapy of BK-virus infection addresses an unmet medical need in immune-compromised patients such as patients living with a kidney transplant, that suffer from infection by a normally harmless virus.
Modulated Imaging is developing and marketing devices for determining oxygenation levels in superficial tissues for patients with potential circulatory compromise.
SafeRide Health is a venture-backed startup founded in 2016 with the mission of improving access to care for the nation’s underserved populations. The SafeRide platform fulfills over 1 million rides per year by managing transportation programs for healthcare systems and states. SafeRide simplifies health system operations, improves patient outcomes, and reduces costs for some of the nation’s leading healthcare systems.
Vectorious Medical Technologies
Vectorious Medical Technologies has developed an implantable microcomputer-based system that enables optimal management of heart failure patients using direct, daily left-atrial pressure (LAP) measurements.
In January 2022 New Directions Behavioral Health, a provider of comprehensive behavioral health solutions, announced its acquisition of Tridiuum, a digital behavioral health company. Tridiuum accelerates patient access to the most appropriate care by automating behavioral health screening, triaging, matching and online scheduling through its easy-to-use system that can be seamlessly integrated with existing platforms.
In June 2020 Novo Nordisk A/S signed an agreement to acquire Corvidia Therapeutics including their lead candidate, ziltivekimab, currently being investigated in a phase 2b trial in cardiovascular disease.
Head, Fresenius Medical Care Ventures
Dr. Andreas Wüpper
Director Investments Europe
Revital (Tali) Hirsch
Director, Venture Investments
Regional Director Product and Marketing Innovation
Venture Innovation Manager, Israel
Our Managing Directors
Dr. Peter Hennke
Memo Therapeutics AG Closes Series B Financing at CHF37 Million Following Oversubscribed CHF23 Million Extension
Proceeds will be used to advance antibody against BK virus through Phase 2 clinical development
SCHLIEREN, Switzerland – February 16, 2022 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the close of an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination of strategic and financial investors, including Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Verve Ventures, Vesalius Biocapital and Zürcher Kantonalbank.
New Directions Behavioral Health Combines with Tridiuum to Create Industry-Leading Technology-Enabled Behavioral Health Company
OVERLAND PARK, Kan., Jan. 14, 2022 /PRNewswire/ -- New Directions Behavioral Health ("New Directions"), a provider of comprehensive behavioral health solutions, today announced its acquisition of Tridiuum, a digital behavioral health company. This combination creates a leading provider of technology-enabled behavioral health services, empowering New Directions' dedicated care teams to supply its more than 15 million members nationally with more direct and immediate access to providers resulting in increased quality of care through measurement-based outcomes.
Alucent Biomedical Announces $35 Million Series B Financing
SALT LAKE CITY, Utah – Oct 1, 2020 – Alucent Biomedical, a privately held medical technology company founded to transform the way vascular disease is treated, today announced the close of a $35 million Series B financing round led by a large multinational strategic investor and joined by another new investor, Fresenius Medical Care Ventures.
Fresenius Medical Care Ventures leads $100 million Series B financing for eGenesis
Fresenius Medical Care, the world’s leading provider of dialysis services and products, has led the $100 million Series B equity financing for eGenesis through its corporate venture capital arm Fresenius Medical Care Ventures GmbH. eGenesis is a leading player in the field of xenotransplantation of kidneys for patients with advanced renal disease.
Founded by Luhan Yang and George Church in 2016, eGenesis is using gene editing technology to enable the transplantation of pig kidneys into humans safely and without an immune response rejecting the organ.
SafeRide Health Announces Series A Funding Round Led by Fresenius Medical Care Ventures
SafeRide, Inc. (“SafeRide Health;” “SafeRide”), a Los Angeles area-based healthcare logistics provider, announced that it has raised an undisclosed Series A equity financing round. Fresenius Medical Care Ventures led the round, with additional contributions from Amplify.LA, Bonfire Ventures, FCA Venture Partners, and Meridian Street Capital.
Digital Health Company Tridiuum Secures $9.5 Million in Series B Financing to Advance its Solution for Integrating Behavioral Health into Total Health
PHILADELPHIA, Pa., Dec. 18, 2018 – Digital health company Tridiuum has secured $9.5 million in Series B financing, which includes equity capital from lead investor Sopris Capital and strategic co-investor Fresenius Medical Care Ventures, and debt funding from Silicon Valley Bank. Series A investors Ben Franklin Technology Partners of Southeastern Pennsylvania and Martinson Ventures participated as well.
Fresenius Medical Care Ventures invests in Israeli medical device company
Fresenius Medical Care Ventures, the venture capital unit of Fresenius Medical Care, announced today that it has invested $2 million in the Series B financing round for Vectorious Medical Technologies (“Vectorious”). The Israeli medical device company raised more than $10 million in this financing round, including a recent grant from the European Union’s Horizon 2020 flagship research and development program.
Vectorious has developed the V-LAP, a first of its kind in-heart microcomputer for left-atrial pressure monitoring. Data from this device is transmitted wirelessly to clinicians, enabling heart failure patients to be managed effectively before their disease advances.
The Series B financing will accelerate Vectorious’ ongoing R&D programs, as well as CE Mark and FDA regulatory approval initiatives.
Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work
Waltham, MA, April 25, 2018 — Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP). Series A investors Apple Tree Partners, MedImmune, the global biologics Research and Development arm of AstraZeneca, and Sofinnova Partners, the founding seed investor, also participated in this round.
Modulated Imaging Completes Series A Funding
Irvine, CA – November 15, 2017 – Modulated Imaging, Inc., announced today that it has closed a $2.86 million Series A financing round to support growing market interest and demand for its innovative light-based imaging technology. This represents the medical device company’s second financing round since July of last year. The round was led by Grey Sky Venture Partners. Also participating was Mitsubishi UFJ Capital Co, Ltd, Fresenius Medical Care Ventures GmbH and, making a second investment in the company, Hamamatsu Photonics K.K. through its wholly-owned subsidiary Photonics Management Corporation.
ExThera Medical Closes Financing Led by Fresenius Medical Care Ventures to Support Commercialization of Innovative Technology to Remove Pathogens from Whole Blood
Martinez, Calif. – June 2, 2016 – ExThera Medical Corporation, the leading developer of innovative blood filtering technology to address major global health problems, today announced that the company has closed a Series B financing round with an equity investment led by new investor Fresenius Medical Care Ventures GmbH. The round included existing investors, and the conversion of the company’s convertible note, for a total of $15.3 million. Other terms were not disclosed.
Fresenius Medical Care Ventures
61352 Bad Homburg